It is still unknown whether targeting the IL-6 signaling pathway would have a causal effect on NAFLD through several drugs targeting this pathway that have been approved or displayed clinical potency for metabolic diseases, inflammatory bowel disease (IBD), and liver and gastrointestinal cancer (Giraldez et al., 2021). Here, IL6 is linked to metabolic dysfunction-associated steatotic liver disease.